Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi‐Center, Open‐Label Phase I Trial

• Published in: Cancer medicine (Malden, MA) Vol. 14; no. 8; pp. e70890 - n/a
• Main Authors: Zhou, Ya‐Lan, Zhang, Jin‐Qiao, Wang, Wei, Bao, Li, Fang, Bai‐Jun, Gao, Da, Su, Li‐Ping, Chen, Wen‐Ming, Yang, Guang‐Zhong
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.04.2025; John Wiley and Sons Inc; Wiley
• Subjects: Adult; Aged; Anthracycline; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bortezomib; Bortezomib - administration & dosage; Bortezomib - adverse effects; Cell cycle; Clinical trials; Dexamethasone; Dexamethasone - administration & dosage; Dexamethasone - adverse effects; Drug Resistance, Neoplasm; efficacy; Female; Humans; Leukemia; Liposomes; Lymphopenia; Male; Middle Aged; Mitoxantrone; Mitoxantrone - administration & dosage; Mitoxantrone - adverse effects; mitoxantrone hydrochloride liposome; Multiple myeloma; Multiple Myeloma - drug therapy; Multiple Myeloma - pathology; Neutropenia; Proteasome inhibitors; Proteasomes; relapsed/refractory multiple myeloma; Remission (Medicine); Response rates; safety; Thrombocytopenia; Toxicity; Treatment Outcome; relapsed/refractory multiple myeloma; mitoxantrone hydrochloride liposome; safety; efficacy

ABSTRACT Backgrounds Mitoxantrone hydrochloride liposome (Lipo‐MIT) has shown clinical benefits in various tumors. However, there is no prospective study evaluating its effectiveness and safety in relapsed/refractory multiple myeloma (RRMM). A phase I trial of bortezomib, Lipo‐MIT, and dexamethasone...